Despite their unproven efficacy and safety concerns, complementary and alternative therapies (CAT) are used by a high proportion of patients with systemic lupus erythematosus (SLE). A prospective survey of past and present CAT use was done on 192 patients (36.5 ± 12.7 years; 106 ± 85 months of disease duration; 94% women) with an SLE diagnosis according to ACR criteria. Quality of life [Short Form 36 (SF-36)] and cumulated damage (SLICC/ACR) were compared between CAT users and non-users. In all, 103 (53.6%; 95% CI: 46.8–60.9) patients were CAT users (median: two remedies/patient): two (1%) in the alternative mode (CAT instead of allopathic treatment); 101 (52.6%) in the complementary mode (CAT in addition to allopathic treatment). A univariate analysis showed CAT users to have higher cumulated damage (P = 0.01) levels, as well as lower physical function (P = 0.05), social function (P = 0.05) and bodily pain (P = 0.02) domain scores in the SF-36 survey. After adjustment for disease duration with a linear model, only differences in bodily pain (P = 0.04) and cumulated damage (P = 0.05) remained statistically significant. CAT use is apparently associated with lower health status in patients with SLE from Yucatan, Mexico. Because the study was cross-sectional, more research is needed to define the directionality of this association.
2 Eisenberg D Kessler R Van R . Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med2001; 135: 344–351.
3.
3 Desmet P . Drug therapy: herbal remedies. N Engl J Med2002; 347: 2046–2056.
4.
4 Eisenberg DM Davis RB Tener SL . Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA1998; 280: 1569–1575.
5.
5 Ramos-Remus C Gutierrez-Urena S Davis P . Epidemiology of complementary and alternative practices in rheumatology. Rheum Dis Clin North Am1999; 25: 789–804.
6.
6 Wootton JC Sparber A . Surveys of complementary and alternative medicine: part IV. Use of alternative and complementary therapies for rheumatologic and other diseases. J Altern Complement Med2001; 7: 715–721.
7.
7 Fautrel B Adam V St-Pierre Y Joseph L Clarke AE Penrod JR . Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide Canadian survey. J Rheumatol2002; 29: 2435–2441.
8.
8 Rao JK Mihaliak K Kroenke K Bradley J Tierney WM Weinberger M . Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med1999; 131: 409–416.
9.
9 Lau CS Lo Y Mok MY . The use of complementary and alternative medicines in rheumatic diseases in Chinese. Arthritis Care Res2001; 45: S13.
10.
10 Alvarez-Hernandez E Casasola-Vargas JC Lino-Perez L Vázquez-Mellado J Vargas RB . [Frequency of use of complementary and alternative medicine in first-time patients of an outpatient rheumatology clinic. An analysis of 800 cases] Frecuencia de uso de medicinas complementarias y alternativas en sujetos que acuden por primera vez al servicio de reumatología. Análisis de 800 casos. Reumatol Clin2006; 2: 183–189.
11.
11 Ramos-Remus C Gamez-Nava JL Gonzalez-López L . Use of alternative therapies by patients with rheumatic diseases in Guadalajara, Mexico: Prevalence, beliefs and expectations. Arthritis Care Res1998; 11: 411–418.
12.
12 Rao JK Kroenke K Mihaliak KA Grambow SC Weinberger M . Rheumatology patients' use of complementary therapies: results from a one-year longitudinal study. Arthritis Rheum2003; 49: 619–625.
13.
13 Breuer GS Orbach H Elkayam O . Use of complementary and alternative medicine among patients attending rheumatology clinics in Israel. Isr Med Assoc J2006; 8: 184–187.
14.
14 Moore AD Petri MA Manzi S . The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum2000; 43: 1410–1418.
15.
15 Leong KP Pong LY Chan SP . Why lupus patients use alternative medicine. Lupus2003; 12: 659–664.
16.
16 Leong KP Pong LY Ng TP Chng HH . The use of traditional Chinese medication in lupus patients in Singapore. APLAR J Rheumatol1997; 1: 116–120.
17.
17 Ramos-Remus C Gamez-Nava JI Gonzalez-Lopez L Suarez-Almazor ME . Use of alternative medicine in a consecutive sample of patients with systemic lupus erythematosus. J Rheumatol1997; 24: 2490–2491 [Letter].
18.
18 Patavino T Brady DM . Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus. Altern Med Rev2001; 6: 460–471.
19.
19 Van Vollenhoven RF . Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother2002; 3: 23–31.
20.
20 Tao X Lipsky PE . The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am2000; 26: 29–50.
21.
21 Hilepo JN Belluci AG Mossey RT . Acute renal failure caused by “cat's claw” herbal remedy in a patient with systemic lupus erythematosus. Nephron1997; 77: 361 (Letter).
22.
22 Kraus A Guerra-Bautista G Alarcon-Segovia D . Salmonella arizona arthritis and septicemia associated with rattlesnake ingestion by patients with connective tissue diseases. A dangerous complication of folk medicine. J Rheumatol1991; 18: 1328–1331.
23.
23 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
24.
25.
25 Stoll T Gordon C Seifert B . Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol1997; 24: 1608–1614.
26.
26 Gladman D Ginzler E Goldsmith C . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
27.
27 Gladman DD Urowitz MB Goldsmith CH . The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40: 809–813.
28.
28 Sutcliffe N Clarke AE Gordon C Farewell V Isenberg DA . The association of socioeconomic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology1999; 38: 1130–1137.
29.
29 Sutcliffe N Clarke AE Levinton C Frost C Gordon C Isenberg DA . Associates of health status in patients with SLE. J Rheumatol1999; 26: 2352–2356.
30.
30 Clarke AE Petri MA Manzi S . An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. J Rheumatol1999; 26: 1500–1511.
31.
31 Wahner-Roedler DL Elikin PL Vincent A . Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program of a tertiary care center. Mayo Clin Proc2005; 80: 55–60.
